RxDoctor Payments DataLook up a doctor →

Sara Sacco, MD

Neurology · Matthews, NCNPI 1861436214

Payments from drug & device makers

$650,725in general payments, 2019–2025

Across 1,757 payments — averaging $370.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$245K
  • Lilly USA, LLC$128K
  • Teva Pharmaceuticals USA, Inc.$96K
  • Biohaven Pharmaceuticals, Inc.$41K
  • Axsome Therapeutics, Inc.$40K
  • Amgen$31K
  • plus $70K from 21 others

What the payments were for

  • Consulting fees$33,9235%
  • Speaking & faculty fees$549,46384%
  • Grants$440%
  • Travel & lodging$41,3216%
  • Food & beverage$25,6334%
  • Education$3410%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$650,725 in reported general payments places this provider in the 90th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$109,303
Medicare patients
78
Services billed
13,817

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe89$74,422
Emgality PenGalcanezumab-Gnlm72$66,995
UbrelvyUbrogepant35$46,452
BotoxOnabotulinumtoxina18$23,780
Ajovy AutoinjectorFremanezumab-Vfrm22$18,211
NeuproRotigotine13$9,923
Sumatriptan Succinate142$4,275
Eletriptan HbrEletriptan Hydrobromide53$3,180
Zolmitriptan13$2,568
Gabapentin104$2,148
RizatriptanRizatriptan Benzoate85$1,986
Duloxetine Hcl69$1,347
Nadolol17$1,157
Naratriptan Hcl33$951
Zonisamide18$793

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Botox$244,649$70,23253 claims
Upsher-smith Laboratories LLCTopiramate$277$34035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 566 neurology providers in North Carolina.

Other neurology in Matthews

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →